

Technology Advisory Committee C Interests Register

Topic [ID6261]

Publication Date: 08/05/2024

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
Elizabeth Thurgar	TAC C Committee Member	Direct- financial	Elizabeth Thurgar has, in the last six months, provided consultancy advice for Kite in an unrelated indication, relapsed or refractory mantle cell lymphoma.	19/02/2024	It was agreed that Elizabeth Thurgar's declaration would not prevent her from participating in discussions on this appraisal
Satish Venkateshan	TAC C Committee Member	Direct- financial	<p>Regeneron has been developing Covid-19 treatments like casirivimab and imdevimab monoclonal antibodies and next generation covid antibody in the pipeline. Satish Venkateshan works for Regeneron, pharmaceuticals/biotech company. Satish Venkateshan also owns shares in the company and has stock options.</p> <p>Satish Venkateshan was conflicted and did not attend this discussion.</p>	19/02/2024	It was agreed that Satish Venkateshan's declaration would prevent him from participating in discussions on this appraisal

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
Dr Kate Ren	TAC C Committee Member	Non-financial professional interests	Dr Kate Ren is a co-author of the EAG report. Dr Kate Ren was conflicted and did not attend his discussion.	19/02/2024	It was agreed that Dr Kate Ren's declaration would prevent her from participating in discussions on this appraisal